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dN4 QUEsTIONNAIRE IN fAmILy PRAcTIcE fOR EvALUATION
Of cLINIcAL mANIfEsTATIONs Of NEUROPAThIc PAIN IN TyPE 2 
dIABETEs PATIENTs TREATEd By LIGhT ThERAPy
N. R. Makarchuk
I. HORBACHEVSKy TERNOPIL STATE MEDICAL UNIVERSITy, TERNOPIL, UKRAINE
Background. Peripheral diabetic polyneuropathy (DPN) is one of the most frequent neurological complications 
of diabetes mellitus (DM). Despite the large number of pharmacological agents, its treatment is not sufficiently 
effective, which necessitates the search for new therapies.
Objective. The aim of the study was to increase the effectiveness of treatment of neuropathic pain in the 
patients with diabetic polyneuropathy by incorporating procedures using polarizing polychromatic non-coherent 
light (Bioptron light therapy) into the complex therapy of this disease.
Methods. We examined 67 patients with type 2 diabetes complicated with diabetic polyneuropathy. Patients 
were divided into two groups: group 1 consisted of 32 patients, who received standard treatment; group 2 com-
prised 35 patients, who additionally underwent 12 light therapy treatments by means of the Bioptron Physiotherapy 
Unit. The evaluation of neuropathic pain intensity was performed using a modified questionnaire DN4.
Results. A positive clinical effect of treatment was evidenced in both groups in 12 days of treatment. In 3 
months, the intensity of complaints was significantly lower (p<0.05) only in the group with additional use of 
polarizing light. In 6 months, the positive effect of the therapy was leveled in the patients of both groups.
Conclusions. The use of the DN4 questionnaire with a modified scale for assessing the parameters of 
neuropathic pain can optimize its diagnosis. The light therapy procedures together with the standard complex 
therapy of diabetic polyneuropathy increase the clinical efficacy of neuropathic pain treatment and help to 
preserve the therapeutic effect within 3 months.
KeY WoRdS: diabetic polyneuropathy; neuropathic pain; DN4 questionnaire; polarized 
polychromatic noncoherent light (Bioptron).
Introduction
Peripheral diabetic polyneuropathy (dPN) 
is a typical early and most frequent complication 
of diabetes mellitus (dM) [1]. It develops due 
to affection of nerve fibers, caused by diabetes 
and occurs in more than 50 % of patients with 
this illness. Polyneuropathy is revealed in both 
young and elderly patients with type 1 and type 
2 diabetes mellitus [2]. There is no single 
classification of peripheral diabetic neuropathy. 
Some authors recommend defining hypohyper­
 glycemic, generalized, focal and multifocal types 
(Thomas P.K. 1997); whereas others insist on 
singling outing asymptomatic, symptomatic and 
marked symptoms (dyck P. J. 1999) or mono, 
polyneuropathy and autonomic polyneuro-
pathy (I. I. dedov et al., 2002). According to the 
protocol of medical care [11], peripheral poly-
neuropathy is divided into somatic (motor, 
sensory and sensory-motor), vegetative and 
mononeuropathy.
To diagnose pathological process in the 
nervous tissue Boulton et al (2005) suggested 
allocating three clinical forms of peripheral dPN 
(silent, acute pain and chronic pain). Chronic 
pain form of dPN is the most commonly reveled 
in the patients with diabetes [1].
The severity of this complication depends 
on its clinical consequences, in particular, 
trophic disorders and neuropathic pain, which 
adversely affect patients’ quality of life. A 
number of questionnaires are used to diagnose 
neuropathic pain [3]. dN4 questionnaire, being 
one of the most practical, where a positive 
response to four or more questions out of ten 
substantiates ‘neuropathic pain’ diagnosis, is 
used as a screening to detect neuropathic pain 
syndromes [4].
despite the large number of pharmacological 
agents, treatment of patients with diabetic 
polyneuropathy is not sufficiently effective [5, 
6, 7], which necessitates the search for new 
methods of treatment. Since the mid-80s, there 
have been physiotherapeutic devices that emit 
visible (wavelength 80-3400 nm) linearly 
polarized (95 %) incoherent (desynchronized in 
time and space) low-energy (non-destructive, 
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with the energy flux intensity of 40 mW/cm2) 
(Pyler) light, and the light stream, transformed 
by polarization, that lacks both ultraviolet and 
a significant part of the infrared rays. Studies 
conducted at the end of the last century proved 
a positive effect of physiotherapeutic procedures 
using this light for treatment of diseases with 
lesions of peripheral nerves [8, 9, 10]. The aim 
of the study is to increase the effectiveness of 
treatment of neuropathic pain in patients with 
diabetic polyneuropathy by including light 
therapy procedures into the complex treatment 
of this disease.
Methods
67 patients were examined (36 males 
(53.7 %) and 31 females (46.3 %)) with type 2 
diabetes and dPN. The diagnosis of dPN was 
based on anamnesis and clinical examination 
data. the age of the examined persons ranged 
from 45 to 65 years old (mean age 57.0±5.2 
years old). duration of diabetes mellitus was 
from 4 to 19 years (average duration 9.4±3.7 
years), and of dPN was from 1 to 12 years 
(which averaged 5.5±2.9 years).
For the convenience of systematization and 
objectification of data comparing, all examined 
patients were divided into two groups: the 1st – 
control group comprised 32 patients with type 
2 dM and dPN, who received standard treatment 
according to a unified clinical protocol of 
primary and secondary (specialized) medical 
care (No.1118, dated december 21, 2012) [11]. 
The 2nd group involved patients undergoing 
standard treatment together with 12 light 
therapy treatments by means of the Bioptron 
Physiotherapy Unit [12]. The duration of the 
procedure was 10 minutes with a directed flow 
of light on the lower limbs. General characteristic 
features of patients with diabetes are presented 
in Table 1.
Clinical examination of patients was perfor­ 
med before the treatment and on the 12th day 
after the beginning of the treatment.
Neuropathic pain was diagnosed using the 
modifi questionnaire dN4 (2005) [13, 14]. The 
questionnaire structure included two blocks of 
questions: 7 questions of the fi block re­ 
vealed sensory symptoms, including sponta- 
neous pain (burning, painful cold, electric 
shocks), paresthesia and dysesthesia (tingling, 
pins and needles, numbness, itching); three 
conclusions of the physician, based on the 
clinical examination, which comprised the 
second block, give the physician the opportunity 
to identify the allodynia and negative sensory 
symptoms. Neuropathic pain was set at a score 
of 4 or more points.
For the details of each question, we modi- 
fied the DN4 questionnaire by ranging the 
intensity (scale 1 to 10) of the sensations listed 
in the first question block.
evaluation of the results was carried out at 
the admission of patients to the hospital and 
in 12 days after the start of diabetic polyneu- 
ropathy treatment. long-term results of the 
therapy were administered in 3 and 6 months 
by performing the call-in poll among the 
patients using the first question block of the 
questionnaire.
The analysis and processing of statistical 
data of clinical examinations results were carried 
out on a personal computer using STATISTICA 
10 and MS excel xP application packages. All data 
are presented as mean value and standard 
deviation (M±σ). Relations between continuous 
variables were examined by the Pearson 
correlation coefficient χ². Comparison of the 
rates between the groups was carried out using 
the Student T-test, and those within the group 
were compared using Wilcoxon matched paired 
test. The difference in rates was considered 
statistically significant at p<0.05.
Results
According to the dN4 questionnaire, 49 
(73.1 %) of the surveyed patients suffered 
neuropathic pain before treatment, which is 
consistent with the literature [15]. no signifi 
differences between the groups were noticed 
before treatment (p>0.05) (Table 2).
Subjective symptoms in the general group of 
patients were presented as follows: 67.2 % of 
patients suffered burning sensation, while 31.34 % 
experienced painful cold. 74.6 % of people were 
disturbed by tingling. 40.29 % of patients with 
diabetes sensed electric shocks. Pins and needles 
sensation and that of numbness troubled 58.2 % 
and 59.7 % of patients respectively. 34.3 % of 
respondents had complains of itching. The 
Table 1. General characteristic features of the patients (M±σ)
Characteristic features 
of the groups of patients
1st group, 
n=32
2nd group, 
n=35 p
Age, years 58.7±5.2 55.6±4.9 р˃0.05
duration of dM, years 8.6±3.3 10.1±4.0 р˃0.05
duration of dPN, years 4.9±2.8 6.0±3.1 р˃0.05
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Table 2. Follow-up of neuropathic pain severity in the examined groups of patients with diabetes 
mellitus according to the DN4 questionnaire before and after treatment (M±σ)
1st group 2nd group P
Before treatment 4.7±1.4 4.8±1.6 p˃0.05
After treatment 3.4±1.5 2.9±1.2 p˃0.05
Notes: * – significant difference before and after treatment (p<0.05).
objective examination of the patients’ lower 
extremities proved that the pain was localized in 
the area with a reduced sensitivity to touching (in 
70.2 %), pricking (in 37.3 %) and in the area of 
irritation with a brush (in 19.4 %), indicating a 
tactile and sensory sensitivity disturbance. The 
intensity of each of the following complaints 
before treatment in the examined groups of 
patients is presented in Fig. 1.
After the course of treatment, a decrease 
in the level of neuropathic pain was evidenced, 
together with a positive dynamics of the in- 
tensity of subjective complaints of the patients.
The analysis of data of the dN4 questionnaire 
proved a decrease in the signs of neuropathic 
pain by 41.7 % (χ²=2.5; p>0.05) in the patients 
of control group, and by 64.0 % (χ²=27.6; p˂0.05) 
in the group with additional light therapy 
procedures. The rate of neuropathic pain 
presence after the course of treatment was 
much lower in the 2nd group.
The study of individual rates of neuropathic 
pain in each of the groups on the 12th day after 
the beginning of treatment proved that the 
patients of the 1st and the 2nd groups experienced 
burning sensation decrease by 15.6 % (χ²=1.6; 
p>0.05) and 34.4 % (χ²=6.9; p˂0.05) respectively. 
Painful cold sensation insignificantly decreased 
by 6.3 % (χ²=0.291; p>0.05) in group 1 and by 
5.7 % (χ2=0.3; p>0.05) in group 2. The sensation 
of electric shocks was reduced by 28.13 % 
(χ²=6.5; p˂0.05) in the patients of the 1st group 
and by 28.13 % (χ²=5.9; p˂0.05) in those of group 
2. Tingling worried the patients with diabetes 
less by 15.6 % (χ²=1.6; p>0.05) of group 1 and 
by 22.9 % (χ²=4.2; p˂0.05) of group 2. Pins and 
needles as well as numbness decreased by 
21.88 % (χ²=3.1; p˂0.05) and 3.1 % (χ²=3.1; 
p>0.05) in the patients of the 1st group, and by 
25.7 % (χ2=4.629; p˂0.05) and 28.6 % (χ²=5.7; 
p<0.05) in those of the 2nd group. Itching began 
to bother less the respondents of the 1st group 
by 3.1 % (χ²=0.1; p>0.05) and by 14.3 % (χ²=1.7; 
p>0.05) those in the 2nd group. The pain, which 
was localized in the area of reduced sensitivity 
to touching, decreased by 15.6 % (χ²=1.9; 
 
 
 
 
 
 
1st group 
2nd group 
1st group 
2nd group 
 
* 
* 
Before treatment In 12 days after treatment 
* 1st group 
2nd group 
* * 
1st group 
2nd group 
* 
* 
In 3 months after treatment In 6 months after treatment 
Fig. 1. Comparison of the intensity of complaints between the patient groups undergoing treatment. 
Notes: sensation of 1 – burning; 2 – painful cold; 3 – electric shocks; 4 – tingling; 5 – pins and needles; 6 – numbness; 7 – itching; 
* – р˂0.05. 
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p>0.05) and 14.3 % (χ2=1.4; p>0.05), to pricking 
by 25 % (χ²=4.4; p˂0.05) and 22,9 % (χ²=4.6; 
p˂0.05), and to irritation with a brush by 6,5 % 
(χ²=0.3; p>0.05) and 5.71 % (χ²=0.7; p˂0.05) in 
the examined groups 1 and 2, respectively 
(Table 3).
The survey of the patients in 3 months after 
the treatment, proved that in the 1st group such 
sensations as burning, painful cold, electric 
shocks, tingling, pinsand needles, numbness 
and itching were experienced by 17 (53.1 %), 10 
(31.3 %), 12 (37.5 %), 20 (62.5 %), 10 (31.3 %), 18 
(56.3 %) and 9 (28.1 %) patients, whereas in the 
2nd group – by 7 (20 %), 8 (22.9 %), 6 (17.1 %), 23 
(65.7 %), 14 (40 %), 11 (31.4 %) and 7 (20 %) 
patients respectively.
The analysis of survey of the patients with 
diabetes mellitus, conducted in 6 months after 
the treatment, proved that the patients with 
diabetes had sensations of burning, painful 
cold, electric shocks, tingling, pins and needles, 
numbness and itching in 22 (68.5 %), 12 
(37.5 %), 14 (43.8 %), 22 (68.5 %), 15 (46.9 %), 21 
(65.6 %) and 9 (28.1 %) cases in group 1, and in 
23 (65.7 %), 10 (28.6 %), 13 (37.1 %), 26 (74.3 %), 
20 (57.1 %), 14 (40 %) and 12 (34.3 %) cases in 
group 2 respectively. The comparison of com- 
plaints intensity between the patient groups is 
presented in Fig. 1.
Discussion
The results of our study are consistent with 
the recent literature [1]. The standard therapy 
(α­lipoic acid, actovegin and complex of vitamins 
of the group B) decreases the intensity of pain 
and neuropathic disorders [11]. The adding of 
light therapy procedures allows not only the 
achievement of this effect, but also its long-term 
preservation [10, 12]. The use of the questionnaire 
dN4 has long been practiced for the diagnosis 
of neuropathic pain [13, 14], but only its modi-
fication [9] allows evaluating the therapy effec­
tiveness. The obtained results prove that signifi­
cant improvement in the dN4 questionnaire’s 
quantitative indicators occurred in 12 days after 
the beginning of treatment and persisted for 
three months after the treatment in both groups. 
At the same time, the intensity of the indicators 
of block 1 of the questionnaire in three months 
after the treatment was considerably less signifi 
in the patients who received additional light 
therapy. Six months later, quantitative and quali­
tative indicators of the presence and inten sity 
of neuropathic pain resumed to the initial level.
Conclusions
Using a modified dN4 questionnaire in the 
patients with type 2 diabetes can improve the 
diagnosis of neuropathic pain.
Table 3. Follow-up of neuropathic pain intensity in the examined groups of patients 
under the influence of therapy (M±σ)
In
de
x Before 
treatment
After treatment in
р1 р2 р3 р4 р512 days 3 months 6 months
1st group
1 4.7±3.7 1.7±1.9 1.7±1.9 4.6±3.5 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
2 2.3±3.3 0.7±1.3 0.8±1.3 2.4±3.4 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
3 2.3±3.4 0.5±1.5 0.6±0.8 2.0±2.6 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
4 3.6±3.5 2.0±2.6 2.2±2.1 3.8±3.2 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
5 2.2±3.7 1.3±2.3 1.4±2.2 2.3±3.1 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
6 3.0±3.3 1.3±2.2 1.5±1.7 3.1±2.9 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
7 1.750±2.828 0.9±1.9 1.7±2.9 1.8±3.1 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
2nd group
1 5.1±3.8 0.2±0.4 0.3±0.6 4.7±3.9 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
2 2.1±3.5 0.5±1.0 0.5±1.1 1.8±3.1 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
3 2.4±3.2 0.4±1.0 0.5±1.3 1.8±2.6 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
4 4.3±3.1 2.0±2.0 2.0±2.6 3.9±3.1 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
5 2.5±2.5 1.1±1.8 1.3±1.8 2.4±2.4 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
6 3.6±3.3 0.4±0.5 0.5±0.9 2.9±3.7 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
7 1.7±2.8 0.4±1.0 0.5±1.3 1.1±2.3 <0.05 ˃0.05 <0.05 <0.05 ˃0.05
Notes: sensation of 1 – burning; 2 – painful cold; 3 – electric shocks; 4 – tingling; 5 – pinsand needles; 6 – numbness; 7 – itching;
р1 – significant differences of indexes before and in 12 days after treatment;
р2 – significant differences of indexes in 12 days and in 3 months after treatment; 
р3 – significant differences of indexes before and in 3 months after treatment;
р4 – significant differences of indexes in 12 days and in 6 months after treatment; 
р5 – significant differences of indexes before and in 6 months after treatment.
N. R. Makarchuk
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The presence of phototherapeutic proce-
dures by the Bioptron together with the standard 
complex therapy of diabetic polyneuropathy has 
a pronounced clinical effect and contributes to 
a 3-month-long reduction of quantitative and 
qualitative indicators of neuropathic pain.
The temporary clinical effect of the use of 
polarizing light in the treatment of diabetic 
polyneuropathy proves the feasibility of stu-
dying new therapies that would influence the 
pathogenesis of neuropathic pain.
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ОПИТУВАЛЬНИК DN4 У ПРАКТИЦІ СІМЕЙНОГО ЛІКАРЯ ДЛЯ ОЦІНКИ 
НЕЙРОПАТИЧНОГО БОЛЮ У ХВОРИХ З ЦУКРОВИМ ДІАБЕТОМ 2-ГО ТИПУ 
ПРИ ЛІКУВАННЯ СВІТЛОТЕРАПІЄЮ
Н. Р. Макарчук 
ТЕРНОПІЛЬСЬКИЙ ДЕРЖАВНИЙ МЕДИЧНИЙ УНІВЕРСИТЕТ ІМЕНІ І. Я. ГОРБАЧЕВСЬКОГО, ТЕРНОПІЛЬ, УКРАЇНА
Вступ. Периферична діабетична полінейропатія є одним з найбільш частих неврологічних ускладнень цукрового 
діабету. Незважаючи на широкий спектр існуючих лікарських засобів, її лікування є недостатньо ефективним, що 
зумовлює пошук нових статегій та засобів. 
Мета дослідження – підвищити ефективність лікування нейропатичного болю у хворих на цукровий діабет 
шляхом включення процедур iз використанням поляризаційного поліхромного некогерентного світла (біоптронна 
світлотерапія).
Методи. Обстежено 67 хворих на діабет 2 типу, який ускладнений діабетичною поліневропатією. Пацієнтів 
було розділено на дві групи: 1 група – 32 пацієнтів, які отримали стандартне лікування; 2 група 35 хворих, які 
додатково пройшли 12 процедур світлотерапії за допомогою світлотерапевтичного пристрою Біоптрон. Оцінку 
інтенсивності невропатичного болю проводили за допомогою модифікованої анкети DN4.
Результати. Через 12 днів лікування позитивний клінічний ефект лікування спостерігався в обох групах. Однак, 
через 3 місяці інтенсивність скарг була значно меншою (p<0,05) в 2-ій групі пацієнтів, які отримували додатково 
лікування поляризаційним світлом. Через 6 місяців ефект терапії був однаковим у пацієнтів обох груп. 
Висновки. Використання опитувальника DN4 з модифікованою шкалою для оцінки параметрів нейропатичного 
болю може оптимізувати його діагностику та оцінку. Світлотерапевтичні процедури у поєднанні зі стандартною 
комплексною терапією діабетичної поліневропатії підвищують клінічну ефективність лікування невропатичного 
болю і допомагають зберегти терапевтичний ефект протягом 3 місяців. 
КЛЮЧОВІ СЛОВА: діабетична поліневропатія; невропатичний біль; опитувальник DN4; поляризоване 
поліхроматичне некогерентне світло (Біоптрон).
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